Skip to content
TrialScanner

NCT03769467

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Phase 1/Phase 2TerminatedATRALeadMRKCollaborator

Registry record

Lead sponsor
Atara Biotherapeutics
Conditions
Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Epstein-Barr Virus Infections; Epstein-Barr Viraemia; Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Primary completion
Aug 19, 2021Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03769467 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03769467: Tabelecleucel in Combination... | TrialScanner